Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients

Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qingsong, Izumchenko, Evgeny, Aliper, Alexander M, Makarev, Evgeny, Paz, Keren, Buzdin, Anton A, Zhavoronkov, Alex A, Sidransky, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785572/
https://www.ncbi.nlm.nih.gov/pubmed/27081524
http://dx.doi.org/10.1038/hgv.2015.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785572/
https://www.ncbi.nlm.nih.gov/pubmed/27081524
http://dx.doi.org/10.1038/hgv.2015.9

Ejemplares similares